Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)
MWN-AI** Summary
Priovant Therapeutics recently announced promising results from their Phase 2 BEACON study, assessing the efficacy of brepocitinib, a dual TYK2 and JAK1 inhibitor, in treating cutaneous sarcoidosis (CS). This skin condition, characterized by chronic inflammatory lesions, currently has no approved treatments, leaving a significant unmet need for effective options. The BEACON study is notable as the first industry-sponsored, placebo-controlled trial for CS to yield positive outcomes.
In the trial, 31 patients were randomized to receive either brepocitinib at dosages of 45 mg or 15 mg, or a placebo, over 16 weeks. The results showed that the 45 mg dose achieved a substantial 22.3-point improvement in the mean Cutaneous Sarcoidosis Activity and Morphology Instrument - Activity score (CSAMI-A) at Week 16 compared to a mere 0.7-point improvement in the placebo group (P<0.0001). Impressively, all patients in the high-dose group exhibited at least a 10-point improvement, demonstrating both statistically and clinically meaningful outcomes.
Furthermore, 69% of patients on the 45 mg dose attained a two-point improvement on the Investigator’s Global Assessment (IGA) scale, compared to 0% in the placebo group (P=0.0047). Lower-dose brepocitinib also demonstrated a noteworthy response, indicating a dose-dependent benefit across various outcomes.
The treatment was well tolerated, with no serious adverse events reported and only mild to moderate adverse events noted. Following these encouraging results, Priovant is preparing to move into Phase 3 trials for brepocitinib in CS, projected to begin in 2026, positioning the drug as a potential transformative therapy for patients suffering from this challenging condition.
MWN-AI** Analysis
Priovant Therapeutics has recently announced promising Phase 2 results for brepocitinib in the treatment of cutaneous sarcoidosis (CS), demonstrating significant clinical efficacy that could position the company favorably within the biotech landscape. The study revealed that patients receiving the 45 mg dose of brepocitinib achieved a remarkable 22.3-point improvement on the CS Activity and Morphology Instrument (CSAMI-A), a crucial endpoint in assessing disease activity. With 100% of these patients achieving at least a 10-point improvement, the drug presents a strong therapeutic option for a largely underserved patient population.
The market response to this announcement is likely to be favorable due to the high unmet need in treating CS, a condition affecting approximately 40,000 adults in the U.S. The absence of approved therapies for this debilitating condition makes brepocitinib a potential market disruptor. Additionally, the positive safety profile—highlighted by the absence of serious adverse events—aligns well with current regulatory expectations, positioning Priovant favorably for its planned Phase 3 study.
Investors should also consider the broader context of Priovant’s portfolio, which includes ongoing Phase 3 studies for dermatomyositis and non-infectious uveitis. As these programs progress, the cumulative results could elevate investor confidence and drive stock performance.
For investors evaluating Priovant, the upcoming FDA engagement regarding the Phase 3 plans will be critical. If the FDA facilitates rapid development, it could catalyze a significant increase in market valuations. Therefore, those with a bullish outlook on autoimmune therapeutics may find Priovant a compelling addition to their portfolios, particularly as developments in brepocitinib continue to unfold.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (? 21.6 P<0.0001)
- All brepocitinib 45 mg patients achieved a clinically meaningful response, with 100% demonstrating at least a 10-point improvement on CSAMI-A
- On the Investigator’s Global Assessment (IGA), 69% percent of brepocitinib 45 mg patients compared to 0% of placebo patients achieved the gold standard two-point improvement to “Clear” (0) or “Almost Clear” (1) (? 69% P=.0047)
- Brepocitinib 15 mg patients also improved considerably, with numerically similar improvement to the 45 mg arm on lower-bar endpoints and evidence of dose-dependent benefit seen on higher bar endpoints and patient reported outcomes
- Brepocitinib was well tolerated during the study treatment period, with no Serious Adverse Events (SAEs) and all Adverse Events (AEs) graded mild or moderate in severity
- Priovant plans to progress CS to a pivotal program with a Phase 3 study starting in calendar year 2026 following engagement with the FDA, representing the third indication with a pivotal program for brepocitinib
DURHAM, N.C., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics today announced positive results from the Phase 2 BEACON study evaluating brepocitinib in cutaneous sarcoidosis (CS). CS is a highly morbid, chronic, and disfiguring condition with no approved therapies, and the BEACON study is the first ever industry-sponsored placebo-controlled trial in the indication to read out positively.
“The BEACON study is a watershed moment for the sarcoidosis field, and most importantly, for our patients,” said Dr. Misha Rosenbach, MD, Professor of Dermatology and Rheumatology and Director of the Cutaneous Sarcoidosis Program at the Hospital of the University of Pennsylvania. “This is an incredible milestone for a historically neglected disease – the study drug showed a clear difference in patients who received the medication compared to placebo, both from the patient and the physician perspective, and appeared to be well tolerated. This is the sort of data you dream of seeing when you look at trial results – and I would call this a transformational moment for sarcoidosis.”
The BEACON study enrolled 31 patients across 15 sites in the United States, randomized 3:2:2 to once daily brepocitinib 45 mg, 15 mg, or placebo with a 16-week treatment period. The brepocitinib 45 mg arm comprised the most treatment-refractory group, with the highest percentage of patients with longstanding disease, damage, and difficult-to-treat plaque-predominant morphology. Despite this, patients in the 45 mg arm achieved meaningful clinical improvement compared to placebo, including 100% response rates on multiple endpoints. Brepocitinib 15 mg patients also improved considerably, with numerically similar improvement to the 45 mg arm on lower-bar endpoints and evidence of dose-dependent benefit seen on higher bar endpoints and patient reported outcomes. Placebo patients experienced almost no improvement, consistent with natural disease course.
On the Cutaneous Sarcoidosis Activity and Morphology Instrument – Activity score (CSAMI-A), brepocitinib 45 mg achieved a 22.3-point mean improvement at Week 16 versus a 0.7-point improvement in placebo (?21.6 P<0.0001). Statistically significant separation was observed as early as Week 4 and maintained at all timepoints thereafter. One hundred percent of brepocitinib 45 mg patients achieved at least a 10-point improvement on CSAMI-A compared to 14% of placebo patients, and 62% of brepocitinib 45 mg patients achieved CSAMI-A <5 (functional remission), compared to 0% of placebo patients.
| Treatment Arm | Mean CSAMI-A Change from Baseline at Week 16 | Achievement of CSAMI-A ? 10-point Reduction at Week 16 | Achievement of CSAMI-A < 5 (Functional Remission) at Week 16 |
| 45 mg (n = 13) | -22.3 | 100% | 62% |
| 15 mg (n = 11) | -22.2 | 73% | 46% |
| Placebo (n = 7) | -0.7 | 14% | 0% |
| 45 mg vs. placebo | ? -21.6; P<0.0001 | ? 86%; P=0.0002 | ? 62%; P=0.0147 |
| 15 mg vs. placebo | ? -21.5; P<0.0001 | ? 58%; P=0.0498 | ? 46%; P=0.1013 |
On the Investigator’s Global Assessment (IGA), 69% of brepocitinib 45 mg patients achieved the gold standard two-point improvement to Clear (0) / Almost Clear (1), compared to 0% of placebo patients (? 69% P=.0047). Brepocitinib 45 mg also demonstrated statistically significant improvement over placebo on key patient reported outcomes, including the King’s Sarcoidosis Questionnaire (KSQ) Skin Domain, the Skindex-16, and the Patient’s Global Impression of Change (PGI-C). On PGI-C, 100% of patients receiving the 45 mg dose reported improvement from baseline, compared to 29% of placebo patients (? 71% P=.0014).
Brepocitinib was well tolerated during the study treatment period, with no Serious Adverse Events (SAEs) and all Adverse Events (AEs) graded mild or moderate in severity. Brepocitinib has been evaluated in more than 1,500 patients and subjects, with an observed safety profile consistent with approved JAK1 and TYK2 inhibitors.
Priovant plans to initiate a Phase 3 program in CS in calendar year 2026, following engagement with FDA.
“We are thrilled with the results of the BEACON study and are excited to rapidly move brepocitinib into Phase 3 development for cutaneous sarcoidosis,” said Ben Zimmer, Priovant CEO. “I would like to thank all of the patients, investigators, and site staff who participated in the study and made this result possible. With the brepocitinib CS program now moving into Phase 3 alongside the dermatomyositis and non-infectious uveitis programs, Priovant continues to advance our goal of developing brepocitinib as a potentially transformational therapy for patients with highly morbid autoimmune diseases underserved by existing treatment options.”
About Cutaneous Sarcoidosis
Cutaneous sarcoidosis (CS) is an inflammatory granulomatous skin disease affecting approximately 40,000 adults in the United States. CS lesions are frequently chronic, may involve extensive body surface area, and are often profoundly disfiguring, leading to substantial psychosocial distress and impaired quality-of-life. Despite this significant unmet therapeutic need, no treatments are currently approved for CS. As a result, many patients rely on prolonged off-label treatment with systemic corticosteroids, immunosuppressants, and biologics, which offer limited efficacy and carry meaningful treatment-related toxicity.
About Priovant
Priovant Therapeutics is a biotechnology company dedicated to developing novel therapies for autoimmune diseases with high morbidity and few available treatment options. The company's lead asset is brepocitinib, a dual selective inhibitor of TYK2 and JAK1. Through dual TYK2/JAK1 inhibition, brepocitinib distinctively suppresses key cytokines linked to autoimmunity—including type I IFN, type II IFN, IL-6, IL-12, and IL-23—with a single, targeted, once-daily oral therapy. Brepocitinib recently generated positive Phase 3 data in dermatomyositis, and an NDA submission is planned for early 2026. Brepocitinib is also being evaluated in a Phase 3 program in non-infectious uveitis and recently generated positive Phase 2 data in cutaneous sarcoidosis, with a Phase 3 study to begin in calendar year 2026. Priovant Therapeutics is a Roivant (Nasdaq: ROIV) company.
Contact
Daniel Herz Roiphe, daniel.herz-roiphe@priovant.com
FAQ**
Given the positive results from the BEACON study of brepocitinib in cutaneous sarcoidosis, how might this influence Roivant Sciences Ltd. Warrant ROIVW in attracting new investment and advancing future clinical trials?
With brepocitinib demonstrating a significant improvement in CSAMI-A scores, what strategic advantages could arise for Roivant Sciences Ltd. Warrant ROIVW as the drug progresses towards a Phase 3 study in 2026?
How do you foresee the market response to brepocitinib’s breakthrough results in cutaneous sarcoidosis impacting the overall valuation of Roivant Sciences Ltd. Warrant ROIVW over the next few years?
In light of brepocitinib's well-tolerated profile and promising efficacy, what implications might these findings have for Roivant Sciences Ltd. Warrant ROIVW in terms of securing partnerships or collaborations for further development?
**MWN-AI FAQ is based on asking OpenAI questions about Roivant Sciences Ltd. (NASDAQ: ROIV).
NASDAQ: ROIV
ROIV Trading
-1.71% G/L:
$28.21 Last:
1,155,726 Volume:
$28.87 Open:
